Clinically validated peptides as templates for de novo peptidomimetic drug design at G-protein-coupled receptors

Current Opinion in Pharmacology

Volumn 3, Issue 5, 2003, Pages 530-543

  Jones, Robert M ^a   Boatman, P Douglas ^a   Semple, Graeme ^a   Shin, Young Jun ^a   Tamura, Susan Y ^a  

^a ARENA PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; APREPITANT; BOSENTAN; CETRORELIX; COMPLEMENT COMPONENT C5; G PROTEIN COUPLED RECEPTOR; GONADORELIN ANTAGONIST; GOSERELIN; HORMONE RECEPTOR STIMULATING AGENT; IMMUNOMODULATING AGENT; L 264930; L 363377; LIGAND; LORATADINE; LOSARTAN; MELANOCORTIN 4 RECEPTOR; N [3 (AMINOMETHYL)CYCLOHEXYLMETHYL] 3 (1H INDOL 3 YL) 2 [(SPIRO[1H INDENE 1,4' PIPERIDIN] 1' YLCARBONYL)AMINO]PROPIONAMIDE; N,N 269100; NEUROTENSIN; OCTREOTIDE; OLANZAPINE; PEPTIDE DERIVATIVE; PROTEIN INHIBITOR; SOMATOSTATIN; SRIF 14; SUMATRIPTAN SUCCINATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; UROTENSIN II; VAPREOTIDE; VASOPRESSIN V2 RECEPTOR;

BINDING AFFINITY; CLINICAL TRIAL; COMBINATORIAL CHEMISTRY; DIARRHEA; DRUG ABSORPTION; DRUG CONFORMATION; DRUG DESIGN; DRUG DISTRIBUTION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG RESEARCH; DRUG SCREENING; DRUG SELECTIVITY; DRUG STABILITY; HUMAN; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN MOTIF; REVIEW; SITE DIRECTED MUTAGENESIS; VALIDATION PROCESS;

COMPLEMENT C5A; DRUG DESIGN; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GONADOTROPIN-RELEASING HORMONE; NEUROTENSIN; PEPTIDE FRAGMENTS; PEPTIDES; PROTEIN PRECURSORS; RECEPTOR, MELANOCORTIN, TYPE 4; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, VASOPRESSIN; SOMATOSTATIN; UROTENSINS;

EID: 0141869940     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2003.06.003     Document Type: Review

References (78)

1. Woodmac PharmaView 2001 [URL: http://www.woodmacresearch.com/phview].
2. Gurrath M. Peptide-binding G protein-coupled receptors: new opportunities for drug design Curr. Med. Chem. 8 2001 1605-1648
3. Bursavich M.G. Rich D.H. Designing non-peptide peptidomimetics in the 21st century: inhibitors targeting conformational ensembles J. Med. Chem. 45 2002 541-558
4. Golebiowski A. Klopfenstein S.R. Portlock D.E. High-throughput organic synthesis of peptide mimetics Curr. Opin. Drug Discov. Dev. 4 2001 428-434
5. Freidinger R.M. Nonpeptidic ligands for peptide and protein receptors Curr. Opin. Chem. Biol. 3 1999 395-406
6. Ripka A.S. Rich D.H. Peptidomimetic design Curr. Opin. Chem. Biol. 2 1998 441-452
7. Janecka A. Zubrzycka M. Janecki T. Somatostatin analogs J. Pept. Res. 58 2001 91-107
8. Hannon J.P. Nunn C. Stolz B. Bruns C. Weckbecker G. Lewis I. Troxler T. Hurth K. Hoyer D. Drug design at peptide receptors: somatostatin receptor ligands J. Mol. Neurosci. 18 2002 15-27
9. Spier A.D. de Lecea L. Cortistatin: a member of the somatostatin neuropeptide family with distinct physiological functions Brain Res. Rev. 33 2000 228-241
10. Yang L. Non-peptide somatostatin receptor ligands Annu. Rep. Med. Chem. 34 1999 209-218
11. Osapay G. Osapay K. Therapeutic applications of somatostatin analogues Exp. Opin. Ther. Pat. 8 1998 855-867
12. Hirschmann R. Nicolau K.C. Pietranico S. Leahy E.M. Slavino J. Arison B.H. Crichy M.A. Spoors P.G. Shakespeare W.C. Sprengeler P.A. et al. De novo design and synthesis of somatostatin non-peptide peptidomimetics utilizing b-d-glucose as a novel scaffolding J. Am. Chem. Soc. 114 1993 9217-9218
13. Prasad V. Birzin E.T. McVaugh C.T. van Rijn R.D. Rohrer S.P. Chicci G. Underwood D.J. Thornton E.R. Smith A.B. III Hirschmann R. Effects of heterocyclic aromatic substituents on binding affinities at two distinct sites of somatostatin receptors. Correlation with the electrostatic potential of the substituents J. Med. Chem. 46 2003 1858-1869
14. 4 selectivity J. Am. Chem. Soc. 120 1998 1368-1373
15. Yang L. Berk S.C. Rohrer S.P. Mosley R.T. Guo L. Underwood D.J. Arison B.H. Birzin E.T. Hayes E.C. Mitra S.W. et al. Synthesis and biological activities of potent peptidomimetics selective for somatostatin receptor subtype 2 Proc. Natl. Acad Sci. USA 95 1998 10836-10841
16. Pasternak A. Pan Y. Marino D. Sanderson P.E. Mosley R. Rohrer S.P. Birzin E.T. Huskey S.-E.W. Jacks T. Schleim K.D. et al. Potent, orally bioavailable somatostatin agonists: good absorption achieved by urea backbone cyclization Bioorg. Med. Chem. Lett. 9 1999 491-496
17. Rohrer S.P. Birzin E.T. Mosley R.T. Berk S.C. Hutchins S.M. Shen D.-M. Xiong Y. Hayes E.C. Parmar R.M. Foor F. et al. Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry Science 282 1998 737-740
18. Souers A.J. Virgilio A.A. Rosenquist S.A. Fenuik W. Ellman J.A. Identification of a potent heterocyclic ligand to somatostatin receptor subtype 5 by the synthesis and screening of β-turn mimetic libraries J. Am. Chem. Soc. 121 1999 1817-1825
19. Liu Q. Pong S.-S. Zeng Z. Zhang Q. Howard A.D. Williams D.L. Davidoff M. Wang R. Austin C.P. McDonald T.P. et al. Identification of urotensin II as the endogenous ligand for the orphan G-protein-coupled receptor GPR14 Biochem. Biophys. Res. Commun. 266 1999 174-178
20. Maguire J.J. Davenport A.P. Is urotensin-II the new endothelin? Br. J. Pharmacol. 137 2002 579-588
21. Flohr S. Kurz M. Kostenis E. Brkovich A. Fournier A. Klabunde T. Identification of nonpeptidic urotensin II receptor antagonists by virtual screening on a pharmacophore model derived from structure-activity relationships and nuclear magnetic resonance studies on urotensin II J. Med. Chem. 45 2002 1799-1805
22. Croston G.E. Olsson R. Currier E.A. Burstein E.S. Weiner D. Nash N. Severance D. Allenmark S.G. Thunberg L. Ma J.-N. Mohell A. O'Dowd B. Brann M.R. Hacksell U. Discovery of the first nonpeptide agonist of the GPR14/urotensin-II receptor: 3-(4-chlorophenyl)-3-(2- (dimethylamino)ethyl)isochroman-1-one (AC-7954) J. Med. Chem. 45 2002 4950-4953
23. Huirne J.A.F. Lambalk C.B. Gonadotropin-releasing-hormone-receptor antagonists Lancet 358 2001 1793-1803
24. Jiang G. Stalewski J. Galyean R. Dykert J. Schteingart C. Broqua P. Aebi A. Aubert M.L. Semple G. Robson P. et al. GnRH antagonists: a new generation of long acting analogues incorporating p-ureido-phenylalanines at positions 5 and 6 J. Med. Chem. 44 2001 453-467
25. Koerber S.C. Rizo J. Struthers R.S. Rivier J.E. Consensus bioactive conformation of cyclic GnRH antagonists defined by NMR and molecular modeling J. Med. Chem. 43 2000 819-828
26. Digilio G. Bracco C. Barbero L. Chicco D. Del Curto M.D. Esposito P. Traversa S. Aime S. NMR conformational analysis of antide, a potent antagonist of the gonadotropin releasing hormone J. Am. Chem. Soc. 124 2002 3431-3442
27. Cho N. Harada M. Imaeda T. Imada T. Matsumoto H. Hayase Y. Sasaki S. Furuya S. Suzuki N. Okubo S. et al. Discovery of a novel, potent, and orally active nonpeptide antagonist of the human luteinizing hormone-releasing hormone (LHRH) receptor J. Med. Chem. 41 1998 4190-4195
28. Sasaki S. Cho N. Nara Y. Harada M. Endo S. Suzuki N. Furuya S. Fujino M. Discovery of a thieno[2,3-d]pyrimidine-2,4-dione bearing a p-methoxyureidophenyl moiety at the 6-position: a highly potent and orally bioavailable non-peptide antagonist for the human luteinizing hormone-releasing hormone receptor J. Med. Chem. 46 2003 113-124
29. Besecke L.M. Diaz G.J. Segreti J.A. Mohning K.M. Cybulski V.A. Rao M. Bush E.N. Randolph J.T. Waid P.L. Haviv F. et al. Pharmacological and endocrine characterization of A-198401, an orally active GnRH antagonist, in intact and castrate male rat models Drug Dev. Res. 52 2001 485-491
30. Anderes K. Luthin D.R. Castillo R. Kraynov E.A. Castro M. Nared-Hood K. Gregory M.L. Pathak V.P. Christie L.C. Paderes G. et al. Biological characterization of a novel, orally active small molecule gonadotropin-releasing hormone (GnRH) antagonist using castrated and intact rats J. Pharmacol. Exp. Ther. 305 2003 688-695
31. Kinkead B. Nemeroff C.B. Neurotensin: an endogenous antipsychotic? Curr. Opin. Pharmacol. 2 2002 99-103
32. Tyler-McMahon B.M. Boules M. Richelson E. Neurotensin: peptide for the next millennium Regul. Pept. 93 2000 125-136
33. Dobner P.R. Barber D.L. Villa-Komaroff L. McKiernan C. Cloning and sequence analysis of cDNA for the canine neurotensin/neuromedin N precursor Proc. Natl. Acad Sci. USA 84 1987 3516-3520
34. Friry C. Feliciangeli S. Richard F. Kitabgi P. Rovere C. Production of recombinant large proneurotensin/neuromedin N-derived peptides and characterization of their binding and biological activity Biochem. Biophys. Res. Commun. 290 2002 1161-1168
35. Craig A.G. Norberg T. Griffin D. Hoeger C. Akhtar M. Schmidt K. Low W. Dykert J. Richelson E. Navarro V. et al. Contulakin-G, an O-glycosylated invertebrate neurotensin J. Biol. Chem. 274 1999 13752-13759
36. Cognetix Inc: [Patent number: WO 2000, 0023092:A1].
37. Cognetix Inc: Cognetix announces issuance of US patent on Contulakin-G to treat pain. First clinical safety study completed with CGX-1160. Cognetix Inc press release, December 5 2002.
38. 1 Brain Res. 695 1995 59-63
39. Machida R. Tokumura T. Tsuchiya Y. Sasaki A. Abe K. Pharmacokinetics of novel hexapeptides with neurotensin activity in rats Biol. Pharm. Bull. 16 1993 43-47
40. Cusak B. Boules M. Tyler B.M. Fauq A. McCormick D.J. Richelson E. Effects of a novel neurotensin peptide analog given extracranially on CNS behaviors mediated by apomorphine and haloperidol Brain Res. 856 2000 48-54
41. Tyler-McMahon B.M. Stewart J.A. Farinas F. McCormick D.J. Richelson E. Highly potent neurotensin analog that causes hypothermia and antinociception Eur. J. Pharmacol. 390 2000 107-111
42. Gully D. Labeeuw B. Biogegrain R. Oury-Donat F. Bachy A. Poncelet M. Steinberg R. Suaud-Chagny M.F. Santucci V. Vita N. et al. Biochemical and pharmacological activities of SR 142948A, a new potent neurotensin receptor antagonist J. Pharmacol. Exp. Ther. 280 1997 802-812
43. Makrides S.C. Therapeutic inhibition of the complement system Pharmacol. Rev. 50 1998 59-87
44. Taylor S.M. Fairlie D.P. Regulators of the anaphylatoxin C5a Exp. Opin. Ther. Patents 10 2000 449-458
45. Yancy K.B. Hammer C.H. Harvath L. Renfer L. Frank M.M. Lawley T.J. Studies of human C5a as a mediator of inflammation in normal human skin J. Clin. Invest. 75 1985 486-495
46. Taylor S.M. Sherman S.A. Kirnarsky L. Sanderson S.D. Development of response-selective agonists of human C5a anaphylatoxin: conformational, biological, and therapeutic considerations Curr. Med. Chem. 8 2001 675-684
47. Finch A.M. Wong A.K. Paczkowski N.J. Wadi S.K. Craik D.J. Fairlie D.P. Taylor S.M. Low-molecular-weight peptidic and cyclic antagonists of the receptor for the compement factor C5a J. Med. Chem. 42 1999 1965-1974
48. Reid R.C. Abbenante G. Taylor S.M. Fairlie D.P. A convergent solution-phase synthesis of the macrocycle Ac-Phe-[Orn-Pro-d-Cha-Trp-Arg], a potent new antiinflammatory drug J. Org. Chem. 68 2003 4464-4471
49. Goodfellow V.S. Saunders J. The melanocortin system and its role in obesity and cachexia Curr. Top. Med. Chem. 3 2003 855-883
50. Butler A.A. Cone R.D. The melanocortin receptors: lessons from knockout models Neuropeptides 36 2002 77-84
51. Weide K. Christ N. Moar K.M. Arens J. Hinney A. Mercer J.G. Eiden S. Schmidt I. Hyperphagia, not hypometabolism, causes early onset obesity in melanocortin-4 receptor knockout mice Physiol. Genomics 13 2003 47-56
52. Fehm H.L. Smolnik R. Kern W. McGregor G.P. Bickel U. Born J. The melanocortin melanocyte-stimulating hormone/adrenocorticotropin(4-10) decreases body fat in humans J. Clin. Endocrinol. Metab. 86 2001 1144
53. Chen L, Cheung AW, Chu X, D W, Swistok J, Y KA: Preparation of selective linear peptides with melanocortin-4 receptor (MC4-R) agonist activity. PCT Int. Appl. (2001), 265 pp. CODEN: PIXXD2 WO 0174844 A2 20011011 CAN 135:304143 AN 2001:747815 CAPLUS.
54. Danho W. Swistok J. Wai-Hing Cheung A. Kurylko G. Franco L. Chu X.J. Chen L. Yagaloff K.Structure-activity relationship of linear peptide Bu-His(6)-DPhe(7)-Arg(8)-Trp(9)-Gly(10)-NH(2) at the human melanocortin-1 and -4 receptors: DPhe(7) and Trp(9) substitution Bioorg. Med. Chem. Lett. 13 2003 649-652
55. Benoit S.C. Schwartz M.W. Lachey J.L. Hagan M.M. Rushing P.A. Blake K.A. Yagaloff K.A. Kurylko G. Franco L. Danhoo W. Seeley R.J. A novel selective melanocortin-4 receptor agonist reduces food intake in rats and mice without producing aversive consequences J. Neurosci. 20 2000 3442-3448
56. Hamilton B.S. Doods H.N. Chronic application of MTII in a rat model of obesity results in sustained weight loss Obes. Res. 10 2002 182-187
57. Kavarana M.J. Trivedi D. Cai M. Ying J. Hammer M. Cabello C. Grieco P. Han G. Hruby V.J. Novel cyclic templates of alpha-MSH give highly selective and potent antagonists/agonists for human melanocortin-3/4 receptors J. Med. Chem. 45 2002 2644-2650
58. Chen L, Cheung AW, Chu X, Danho W, Swistok J, Wang Y, Yagaloff KA: Preparation of cyclic peptides having melanocortin-4 receptor (MC4-R) agonist activity. PCT Int. Appl. (2002), 230 pp. CODEN: PIXXD2 WO 0218437 A2 20020307 CAN 136:217052 AN 2002:171949 CAPLUS.
59. Sebhat I.K. Martin W.J. Ye Z. Barakat K. Mosley R.T. Johnston D.B. Bakshi R. Palucki B. Weinberg D.H. MacNeil T. et al. Design and pharmacology of N-[(3R)-1,2,3,4-tetrahydroisoquinolinium- 3-ylcarbonyl]-(1R)-1-(4-chlorobenzyl)- 2-[4-cyclohexyl-4-(1H-1,2,4-triazol- 1-ylmethyl piperidin-1-yl]-2-oxoethylamine (1), a potent, selective, melanocortin subtype-4 receptor agonist J. Med. Chem. 45 2002 4589-4593
60. Backer RT, Briner K, Collado CI, De Frutos-Garica O, Doecke CW, Fisher MJ, Garcia-Paredes C, Kuklish SL, Mancoso V, Martinelli MJ: Preparation of piperazinyl and hexahydro-1,4-diazepinyl amino acid derivatives as melanocortin receptor agonists. PCT Int. Appl. (2002), 554 pp. CODEN: PIXXD2 WO 0259095 A1 20020801 CAN 137:140775 AN 2002:575055 CAPLUS.
61. Ishikawa S.-E. Schrier R.W. Pathophysiological roles of arginine vasopressin and aquaporin-2 in impaired water excretion Clin. Endocrinol. (Oxf) 58 2003 1-17
62. Fjellestad-Paulsen A. Hoeglund P. Lundin S. Paulsen O. Pharmacokinetics of 1-deamino-8-d-arginine vasopressin after various routes of administration in healthy volunteers Clin. Endocrinol. (Oxf) 38 1993 177-182
63. Czernichow P. Treatment of diabetes insipidus with Minirin. Switch from nasal to oral administration Ann. Endocrinol. (Paris) 59 1998 407-409
64. Hougaard C. Matthiesen T.B. Rittig S. Djurhuus J.C. Bioavailability and pharmacokinetics of desmopressin in elderly men Scand. J. Urol. Nephrol. Suppl. 183 1997 53-54
65. Sugg E.E. Nonpeptide agonists for peptide receptors: lessons from ligands Annu. Rep. Med. Chem. 32 1997 277-283
66. 2 receptor Mol. Pharmacol. 52 1997 16-20
67. Hayashi I. Ishihara K. Kumagai Y. Majima M. Proinflammatory characteristics of a nonpeptide bradykinin mimic, FR190997, in vivo Br. J. Pharmacol. 133 2001 1296-1306
68. Trybulski E.J. Vasopressin receptor modulators: from non-peptide antagonists to agonists Annu. Rep. Med. Chem. 36 2001 159-168
69. Slusarz R. Kazmierkiewicz R. Lammek B. Theoretical conformational analysis of six arginine vasopressin analogs with the L-naphthylalanine in position 3 J. Pept. Res. 56 2000 352-359
70. 2 receptor agonists: structural requirements for an agonist having 1-(4-aminobenzoyl -2,3,4,5-tetrahydro-1H-1-benzazepine as a template J. Med. Chem. 43 2000 4388-4397
71. 2 receptor agonists Exp. Opin. Ther. Patents 12 2002 1249-1258
72. Caggiano T.J. WAY-VNA-932 Drugs of the Future 27 2002 248-253
73. Mark M. NN-2211 Novo Nordisk IDrugs 6 2003 251-258
74. Holst J.J. Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1 Diabetes Metab. Res. Rev. 18 2002 430-441
75. Lee D. George S.R. O'Dowd B.F. Novel G-protein-coupled-receptor genes expressed in the brain: continued discovery of important therapeutic targets Expert. Opin. Ther. Targets 6 2002 185-202
76. Civelli O. Nothacker H.P. Saito Y. Wang Z. Lin S.H. Reinscheid R.K. Novel neurotransmitters as natural ligands of orphan G-protein-coupled receptors Trends Neurosci. 24 2001 230-237
77. Howard A.D. McAllister G. Feighner S.D. Liu Q. Nargund R.P. Van der Ploeg L.H. Patchett A.A. Orphan G-protein-coupled receptors and natural ligand discovery Trends Pharmacol. Sci. 22 2001 132-140
78. Lee D.K. George S.R. Evans J.F. Lynch K.R. O'Dowd B.F. Orphan G-protein-coupled receptors in the CNS Curr. Opin. Pharmacol. 1 2001 31-39